Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

6,683 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prognostic Impact of Early Treatment Interruption of Nivolumab Plus Ipilimumab Due to Immune-Related Adverse Events as First-Line Therapy for Metastatic Renal Cell Carcinoma: A Multi-Institution Retrospective Study.
Ishihara H, Nemoto Y, Nakamura K, Ikeda T, Tachibana H, Fukuda H, Yoshida K, Kobayashi H, Iizuka J, Shimmura H, Hashimoto Y, Takagi T, Ishida H, Kondo T, Tanabe K. Ishihara H, et al. Among authors: ikeda t. Target Oncol. 2021 Jul;16(4):493-502. doi: 10.1007/s11523-021-00825-2. Epub 2021 Jun 26. Target Oncol. 2021. PMID: 34173936
Comparison of Outcomes Between Therapeutic Combinations Based on Immune Checkpoint Inhibitors or Tyrosine Kinase Inhibitor Monotherapy for First-Line Therapy of Patients with Advanced Renal Cell Carcinoma Outside of Clinical Trials: A Real-World Retrospective Multi-Institutional Study.
Ishihara H, Nemoto Y, Nakamura K, Tachibana H, Ikeda T, Fukuda H, Yoshida K, Kobayashi H, Iizuka J, Shimmura H, Hashimoto Y, Kondo T, Takagi T. Ishihara H, et al. Among authors: ikeda t. Target Oncol. 2023 Mar;18(2):209-220. doi: 10.1007/s11523-023-00956-8. Epub 2023 Mar 21. Target Oncol. 2023. PMID: 36941516
Association Between Kidney Function and Outcomes Following Immune Checkpoint Inhibitor-Based Combination Therapy in Patients With Advanced Renal Cell Carcinoma.
Ishihara H, Nemoto Y, Tachibana H, Ikeda T, Fukuda H, Yoshida K, Kobayashi H, Iizuka J, Shimmura H, Hashimoto Y, Kondo T, Takagi T. Ishihara H, et al. Among authors: ikeda t. Clin Genitourin Cancer. 2024 Apr;22(2):549-557.e5. doi: 10.1016/j.clgc.2024.01.010. Epub 2024 Jan 15. Clin Genitourin Cancer. 2024. PMID: 38281878
First-line dual immune checkpoint inhibitor therapies versus combination therapies comprising immune checkpoint inhibitors and tyrosine kinase inhibitors for advanced renal cell carcinoma: a comparative analysis of the effectiveness using real-world data.
Ishihara H, Omae K, Nemoto Y, Ishiyama R, Tachibana H, Nishimura K, Ikeda T, Kobari Y, Fukuda H, Yoshida K, Shimmura H, Hashimoto Y, Iizuka J, Kondo T, Takagi T. Ishihara H, et al. Among authors: ikeda t. Int J Clin Oncol. 2024 Apr;29(4):473-480. doi: 10.1007/s10147-024-02471-w. Epub 2024 Feb 12. Int J Clin Oncol. 2024. PMID: 38345708
6,683 results